Trial Profile
Phase I, Open-label, Randomized, Two Part, Three-Period, Two-Sequence, Cross-over Study to Investigate the Relative Bioavailability of a Tablet Formulation Compared to Powder-in-Capsule of M7583 Including a Food Effect Evaluation for the Tablet in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Jul 2023
Price :
$35
*
At a glance
- Drugs TL 895 (Primary)
- Indications B-cell lymphoma
- Focus Pharmacokinetics
- Sponsors Merck KGaA
- 15 Jun 2023 Results assessing the pharmacokinetics and bruton tyrosine kinase occupancy pharmacodynamics of TL-895 in fasted and fed states, and effect of acid reducingagents on TL-895 PK and PD in fed healthy subjects, presented at the 28th Congress of the European Haematology Association.
- 15 Jun 2023 Results by deriving data from this and other study developing and validating a mechanistic absorption and pharmacokinetic model of covalent Btk inhibitor Tl- 895 to evaluate the influence of food and acid reducing agents, presented at the 28th Congress of the European Haematology Association
- 22 Jan 2018 Status changed from active, no longer recruiting to completed.